Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer

被引：10

作者：

Inoue, A ^{[1
]}

Kunitoh, H ^{[1
]}

Mori, K ^{[1
]}

Nukiwa, T ^{[1
]}

Fukuoka, M ^{[1
]}

Saijo, N ^{[1
]}

机构：

[1] Natl Canc Ctr, Dept Med Oncol, Chuo Ku, Tokyo, Japan

来源：

LUNG CANCER | 2002年 / 38卷 / 02期

关键词：

chemotherapy; docetaxel; elderly; non-small cell lung cancer; phase; 1; weekly;

D O I：

10.1016/S0169-5002(02)00185-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent experience with weekly administration of docetaxel has demonstrated less myelotoxicity and suggested that this regimen holds promise for elderly patients at the high risk of myelosuppression. However, in this phase I trial of weekly docetaxel conducted only in elderly patients (70 years old or more) with non-small cell lung cancer (NSCLC), the toxicity profile was markedly different from that in previous reports. The dose-limiting toxicities were neutropenia, diarrhea and infection. all of which were observed at a dose of 30 mg/m(2)/week and the maximum-tolerated dose by protocol definition was 30 mg/m(2)/wewk. Although other hematological and non-hematological toxicities observed in this treatment were generally moderate and were kell tolerated by elderly patients with NSCLC, the risk of myelosuppression still requires careful attention. (C) 2002 Published by Elsevier Science Ireland Ltd.

引用

页码：205 / 209

页数：5

共 19 条

[1]

BELANI CP, 2000, WORLD C LUNG CANC, V9

[2] Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer [J].